Targeted drug discovery has traditionally focused on inhibiting or modulating the function of abnormal proteins. But many more diseases could potentially be treated by controlling the expression of abnormal and normal genes. Listen to Dr. Eric R. Olson of Syros Pharmaceuticals explain how epigenomics is enabling a paradigm shift in drug discovery.
Audio PlayerFor the best experience using our website, we recommend that you upgrade to a newer version or use another web browser. A list of the most popular web browsers can be found below.
Click on an icon below to go to the download page or close this notice to continue with the current experience.